Journal of Cancer Research and Clinical Oncology

, Volume 135, Issue 9, pp 1277–1285

EpCAM is overexpressed in gastric cancer and its downregulation suppresses proliferation of gastric cancer

Original Paper



To identify the role of epithelial cellular adhesion molecule (EpCAM) in gastric cancer growth and explore the potential value of EpCAM monoclonal antibody as new therapeutic strategy for gastric cancer.


The expression of EpCAM was determined by immunohistochemistry staining in gastric cancer tissues, RT-PCR and Western blot in cell lines. EpCAM expression in cell lines was downregulated by small interfering RNA. Then the effects of EpCAM on gastric cancer cell growth in vivo and in vitro were determined by MTT, FCM analysis, clone formation assay and tumor formation assay. Additionally, western blot was used to detect the effect of EpCAM on cell cycle-relevant factor cyclin D1.


EpCAM was found to be overexpressed in gastric cancer tissues and cell lines. Downregulation of EpCAM resulted in a decrease of cell proliferation and cell cycle arrest in AGS and SGC7901 cells, which had high endogenous EpCAM expression. EpCAM downregulation also suppressed tumor formation in nude mice. Moreover, EpCAM repression in gastric cancer cells could downregulate cyclin D1.


EpCAM was a potential oncogene and contributed to the growth of gastric cancer. Our data first provided compelling evidence of potential value of EpCAM in the therapy of gastric cancer in clinic.


EpCAM Gastric cancer siRNA Proliferation 


  1. Baeuerle PA, Gires O (2007) EpCAM (CD326) finding its role in cancer. Br J Cancer 96:417–423. doi:10.1038/sj.bjc.6603494 PubMedCrossRefGoogle Scholar
  2. Balzar M, Winter MJ, de Boer CJ et al (1999) The biology of the 17–1A antigen (Ep-CAM). J Mol Med 77:699–712. doi:10.1007/s001099900038 PubMedCrossRefGoogle Scholar
  3. Braun S, Vogl FD, Naume B et al (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353:793–802. doi:10.1056/NEJMoa050434 PubMedCrossRefGoogle Scholar
  4. Calabrese G, Crescenzi C, Morizio E et al (2001) Assignment of TACSTD1 (alias TROP1, M4S1) to human chromosome 2p21 and refinement of mapping of TACSTD2 (alias TROP2, M1S1) to human chromosome 1p32 by in situ hybridization. Cytogenet Cell Genet 92:164–165. doi:10.1159/000056891 PubMedCrossRefGoogle Scholar
  5. Chaudry MA, Sales K, Ruf P et al (2007) EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges. Br J Cancer 96:1013–1019. doi:10.1038/sj.bjc.6603505 PubMedCrossRefGoogle Scholar
  6. Generali D, Berruti A, Brizzi MP et al (2006) Hypoxiainducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clin Cancer Res 12:4562–4568. doi:10.1158/1078-0432.CCR-05-2690 PubMedCrossRefGoogle Scholar
  7. Gladden AB, Diehl JA (2005) Location, location, location: the role of cyclin D1 nuclear localization in cancer. J Cell Biochem 96:906–913. doi:10.1002/jcb.20613 PubMedCrossRefGoogle Scholar
  8. Gulubova MV (2002) Expression of cell adhesion molecules, their ligands and tumour necrosis factoralpha in the liver of patients with metastatic gastrointestinal carcinonoms. Histochem J 34:67–77. doi:10.1023/A:1021304227369 PubMedCrossRefGoogle Scholar
  9. Hartung G, Hofheinz RD, Dencausse Y et al (2005) Adjuvant therapy with edrecolomab versus observation in stage II colon cancer: a multicenter randomized phase III study. Onkologie 28:347–350. doi:10.1159/000084595 PubMedCrossRefGoogle Scholar
  10. Kaminishi M (2005) Diversity of gastric cancinogenesis. Oncology 69:1–8. doi:10.1159/000086624 PubMedCrossRefGoogle Scholar
  11. Münz M, Kieu C, Mack B et al (2004) The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene 23:5748–5758. doi:10.1038/sj.onc.1207610 PubMedCrossRefGoogle Scholar
  12. Osada S, Kanematsu M, Imai H et al (2008) Hepatic fibrosis influences the growth of hepatocellular carcinoma. Hepatogastroenterology 55:184–187PubMedGoogle Scholar
  13. Osta WA, Chen Y, Mikhitarian K et al (2004) EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 64:5818–5824. doi:10.1158/0008-5472.CAN-04-0754 PubMedCrossRefGoogle Scholar
  14. Pantel K, Woelfle U (2005) Detection and molecular characterization of disseminated tumour cells: implication for anticancer therapy. Biochim Biophys Acta 1756:53–64PubMedGoogle Scholar
  15. Ploverini PJ (1996) Cellular adhesion molecules: newly identified mediators of angiogenesis. Am J Pathol 148:1023–1029Google Scholar
  16. Punt CJ, Nagy A, Douillard JY et al (2002) Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomized study. Lancet 360:671–677. doi:10.1016/S0140-6736(02)09836-7 PubMedCrossRefGoogle Scholar
  17. Riethmüller G, Schneider-Gädicke E, Schlimok G et al (1994) Randomised trial of monoclonal antibody for adjuvant therapy of resected Duke’s C colorectal carcinoma. Lancet 343:1177–1183. doi:10.1016/S0140-6736(94)92398-1 PubMedCrossRefGoogle Scholar
  18. Seligson DB, Pantuck AJ, Liu X et al (2004) Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma. Clin Cancer Res 10:2659–2669. doi:10.1158/1078-0432.CCR-1132-03 PubMedCrossRefGoogle Scholar
  19. Songun I, Litvinov SV, van de Velde CJ et al (2005) Loss of Ep-CAM (CO17–1A) expression predicts survival in patients with gastric cancer. Br J Cancer 92:1767–1772. doi:10.1038/sj.bjc.6602519 PubMedCrossRefGoogle Scholar
  20. Spizzo G, Obrist P, Ensinger C et al (2002) Prognostic significance of Ep-CAM and Her-2/neu overexpression in invasive breast cancer. Int J Cancer 98:883–888. doi:10.1002/ijc.10270 PubMedCrossRefGoogle Scholar
  21. Trebak M, Begg GE, Chong JM et al (2001) Oligomeric state of the colon carcinoma-associated glycoprotein GA733–2 (EPCAM/EGP40) and its role in GA733-mediated homotypic cell-cell adhesion. J Biol Chem 276:2299–2309. doi:10.1074/jbc.M004770200 PubMedCrossRefGoogle Scholar
  22. Trzpis M, McLaughlin PM, de Leij LM et al (2007) Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am J Pathol 171:386–395. doi:10.2353/ajpath.2007.070152 PubMedCrossRefGoogle Scholar
  23. Varga M, Obrist P, Schneeberger S et al (2004) Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival. Clin Cancer Res 10:3131–3136. doi:10.1158/1078-0432.CCR-03-0528 PubMedCrossRefGoogle Scholar
  24. Went P, Vasei M, Bubendorf L et al (2006) Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 94:128–135. doi:10.1038/sj.bjc.6602924 PubMedCrossRefGoogle Scholar
  25. Xie X, Wang CY, Cao YX et al (2005) Expression pattern of epithelial cell adhesion molecule on normal and malignant colon tissues. World J Gastroenterol 11:344–347PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  1. 1.State Key Laboratory of Cancer BiologyDigestive Diseases of Xijing Hospital, Fourth Military Medical UniversityXi’anPeople’s Republic of China

Personalised recommendations